FDA Explains Why It Approved Apple Watch's De Novo Despite Missing Primary Endpoint
Executive Summary
De novo summary documents published by the US FDA sheds more light on the agency’s work approving two de novos for Apple Watches last year. At the time, the approvals sparked concern from industry stakeholders on whether the company received preferential treatment. Former FDA Commissioner Scott Gottlieb pushed back against the notion in a lengthy blog post late last year.
You may also be interested in...
FDA Codifies Down-Classification For Devices Such As The Apple Watch ECG App
The agency has codified its over-the-counter ECG software class II classification, which means sponsors can continue to benefit from filing for such apps through the less burdensome 510(k) pathway.
Senators Push Back On Global Digital Taxes, While US Pulls Out Of OECD Technology Tax Talks
Two US senators said last week that Organization for Economic Cooperation and Development (OECD) member countries should drop plans to impose digital taxes on US businesses – a scheme that would impact firms that make digital health devices, including Apple, Siemens, Johnson & Johnson and IBM.
Apple And J&J Collaborate On Large Atrial Fibrillation Study
The Heartline Study is evaluating how the Apple Watch can identify and predict atrial fibrillation while improving cardiovascular outcomes and patients’ adherence to anticoagulant drugs.